GEODE CAPITAL MANAGEMENT, LLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 108 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$3,265,522
-4.3%
2,766,937
+14.3%
0.00%
Q2 2023$3,413,339
+77.5%
2,420,808
+88.8%
0.00%
Q1 2023$1,923,000
+129920.3%
1,282,000
+1.4%
0.00%
Q4 2022$1,479
-99.9%
1,264,409
+1.1%
0.00%
Q3 2022$1,413,000
-28.4%
1,251,156
+0.1%
0.00%
Q2 2022$1,974,000
-43.7%
1,249,372
-45.1%
0.00%
Q1 2022$3,504,000
-38.6%
2,275,973
-2.3%
0.00%
-100.0%
Q4 2021$5,708,000
-3.3%
2,330,151
-0.5%
0.00%0.0%
Q3 2021$5,900,000
-11.5%
2,341,514
+0.1%
0.00%0.0%
Q2 2021$6,664,000
+124.1%
2,338,584
+84.7%
0.00%
Q1 2021$2,974,000
+58.7%
1,265,951
+18.8%
0.00%
Q4 2020$1,874,000
+96.0%
1,065,289
+4.3%
0.00%
Q3 2020$956,000
+7.7%
1,021,5440.0%0.00%
Q2 2020$888,000
-36.1%
1,021,544
-39.1%
0.00%
Q1 2020$1,389,000
-50.3%
1,677,519
-46.5%
0.00%
Q4 2019$2,792,000
+85.0%
3,137,454
+103.6%
0.00%
Q3 2019$1,509,0001,540,7880.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2019
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$39,477,0003.01%
Raffles Associates 2,080,536$2,351,0002.51%
Defender Capital, LLC. 5,184,035$5,862,0002.30%
Prescott General Partners LLC 1,851,851$2,093,0000.16%
DAFNA Capital Management LLC 140,000$158,0000.04%
Fort Sheridan Advisors LLC 83,931$95,0000.03%
Long Focus Capital Management, LLC 215,000$243,0000.02%
XTX Topco Ltd 72,807$82,0000.02%
Ergoteles LLC 490,895$555,0000.02%
Beirne Wealth Consulting Services, LLC 45,000$51,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders